EARLY DIALOGUE WITH HEALTH TECHNOLOGY ASSESSMENT BODIES: A EUROPEAN PERSPECTIVE

Author:

Cuche Matthieu,Beckerman Rachel,Chowdhury Cyrus A.,van Weelden Marije A.

Abstract

Introduction: Evidence requirements may differ across HTA bodies, and so pharmaceutical companies must plan to synergize their evidence generation strategy, across global regulatory and HTA bodies. Until recently, companies had no official platform to discuss the clinical development of a drug with HTA bodies; however, this is changing.Objectives: To achieve broad usage in the EU, products must achieve both regulatory and reimbursement approval, the latter of which is based on HTA appraisal in many markets. The objective of this study is to present and evaluate the different options available for early HTA consultation (during drug development/Phase III) in the major European markets from the industry perspective.Methods: An exploratory (nonsystematic) literature review was performed to identify the European markets offering early HTA consultations, and each process was analyzed using a set of predefined metrics that are relevant to industry (the ability to consult with the regulatory body in parallel, consultation fees, length of consultation meeting, language of consultation meeting, maximum number of pharmaceutical company employees attending, procedural timelines, nature of data for which consultative advice can be sought, the output of the process, and the ability to involve external experts).Results: Four different types of early HTA consultation processes were identified across the major European HTA markets. The nature of these processes varied in terms of the types and number of questions that can be addressed, the length of the meeting, the reporting output, and the ability to involve external experts.Conclusions: The availability of various options for early HTA consultation may help to avoid a mismatch between the evidence generated by means of a product's clinical development program, and the evidence expected by HTA bodies and payers, which can facilitate the pricing and reimbursement process upon a product's market authorization.

Publisher

Cambridge University Press (CUP)

Subject

Health Policy

Reference20 articles.

1. Gemeinsame Bundesausschuss. Beschlusse uber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Funften Buches Sozialgesetzbuch (SGB V): Linagliptin. 2012.

2. EUnetHTA. Final minutes of EMA/EUnetHTA meeting. 2013. EUnetHTA. http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/EUnetHTA-EMA%20f-t-f%20meeting%20summary%2020130514%20London%20UK.pdf (accessed June 14, 2013).

3. Moseley J . HTA-EMA scientific advice. 2012. Presented at the TOPRA Annual 2012 Symposium. Dublin, Ireland. October 1, 2012.

4. Scottish Medicines Consortium. Ipilimumab (Yervoy®) 5mg/mL concentrate for solution for infusion, SMC No. (779/12). Glasgow: Scottish Medicines Consortium; 2011.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3